Delivery Order SPE2DB20D1100-SPE2DB25FC9V1
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xeomin 50 unit vials valued at $10,941.84. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with a completion date of September 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under the...
- The Defense Logistics Agency awarded a $19,569.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 3, 2025, for the supply of Xeomin 100 Unit Vials, with completion required by January 27, 2025. This non-competitive delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic applications. This $10,057.32 firm fixed-price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by September 22, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $23,467.08 to AmerisourceBergen Drug Corp for the supply of Xeomin 100 Unit Vials, with an ultimate completion date of September 19, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Xeomin 200 unit vials valued at $46,934.16, with completion scheduled for October 6, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $9,118.20 to AmerisourceBergen Drug Corp for the supply of Xeomin 50 Unit Vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, utilizes firm fixed pricing with no set-aside designation, indicating open and competitive procurement. Performance will take place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xeomin 100 unit vials, valued at $23,467.08, with an ultimate completion date of October 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a $8,381.10 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin on September 25, 2025, with an ultimate completion date of October 17, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract does not utilize a set-aside designation and...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on May 9, 2025, for the supply of Xeomin 200 Unit Vials, with a ceiling value of $46,934.16 and a firm fixed price structure. This is a non-set-aside competitive award, with performance scheduled for completion by June 2, 2025, at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,823.64 for 50-unit vials of Xeomin, a botulinum toxin injection used for therapeutic and cosmetic applications. This firm fixed-price delivery order, awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, represents a non-competitive set-aside award issued under the company's larger indefinite delivery contract. The work will be performed at AmerisourceBergen's corporate...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FC9V1Delivery Order
The Defense Logistics Agency awarded a $9,118.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xeomin 50 Unit Vials, with an ultimate completion date of July 11, 2025. This non-set-aside contract is a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. AmerisourceBergen's comprehensive IDC vehicle enables the company to supply a wide range of pharmaceutical products and medical commodities globally to support military healthcare programs and other federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. This particular delivery order for Xeomin, a botulinum toxin preparation used in medical and cosmetic applications, reflects the company's capability to fulfill specialized pharmaceutical requirements through competitive federal contracting. The arrangement demonstrates DLA's strategy of leveraging prime vendor relationships to ensure efficient and reliable access to essential medical supplies across the military healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.1k | 6/18/25 |